Gene Therapy 张咸宁 [email protected] Tel : 13105819271; 88208367 Office: A705, Research...
-
Upload
marybeth-lynch -
Category
Documents
-
view
259 -
download
0
Transcript of Gene Therapy 张咸宁 [email protected] Tel : 13105819271; 88208367 Office: A705, Research...
![Page 1: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/1.jpg)
Gene TherapyGene Therapy
Tel : 13105819271; 88208367 Office: A705, Research Building
2012/09
![Page 2: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/2.jpg)
Learning Objectives
1. Traditional managements
2. Gene therapy
![Page 3: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/3.jpg)
Intervention Substance or Technique
Disease
Drug/diatary avoidance Antimalarial drugs G6PD deficiency
Dietary restriction Phe
Gal
Cholesterol
PKU
Galactosemia
Familial hypercholesterolemia
Replacement of deficient product
Thyroxine Congenital hypothyroidism
Protein drug therapy Penicillamine Wilson disease
Replacement of deficient enzyme/protein
Blood transfusion SCID
Treatment of Genetic Disease by Metabolic Manipulation
![Page 4: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/4.jpg)
Wilson disease: Cu toxicity, AR
Wilson SAK. Brain, 1912; 34:295-507
![Page 5: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/5.jpg)
Wilson disease:Before/After therapy
![Page 6: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/6.jpg)
Gene therapy
The medical procedure involves either replacing, manipulating, or supplementing nonfunctional genes with healthy genes.
OR
“Everyone talks about the human genome,
but what can we do with it?”
![Page 7: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/7.jpg)
Impact of the Genome Project on Medicine
•Facilitate identification of genes associated with complex disorders ie. Cardiovascular disease, cancer•provides more therapeutic targets-in turn enhances our ability to treat cause of disease instead of symptoms•bioinformatics, array technology, proteomics -enable a systems approach to biomedical research
![Page 8: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/8.jpg)
Monogenic Diseases Which May Be Candidates For Gene Therapy
Sickle cell anemia/Thal Bone MarrowCongenital immune deficiencies Bone MarrowLysosomal storage and metabolic Bone Marrow ---------------------------------------------------------------Cystic fibrosis Lung -
airways ---------------------------------------------------------------Muscular dystrophy Muscle ---------------------------------------------------------------Hemophilia A or B LiverUrea cycle defects LiverFamilial hypercholesterolemia Liver
![Page 9: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/9.jpg)
Types Of Conditions That May Be Treated By Gene Therapy
Monogenic Diseases (>1,000 known)
Cancer, Leukemia
Infectious (AIDS, Hep C)
Cardiovascular
Neurologic
![Page 10: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/10.jpg)
![Page 11: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/11.jpg)
Technical Requirements for Successful Gene Therapy
1. Normal gene must be cloned.
2. Effective method for gene delivery to cells.
3. Inserted gene expressed at appropriate level.
4. Safe for patient and public.
5. More medically beneficial and/or cost-
effective than other treatments.
![Page 12: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/12.jpg)
Gene Delivery Can Be: I. Ex vivo – gene into isolated cells
II. In vivo – gene directly into patient
a) Systemic injection +/- targeted localization +/- targeted expression
b) Localized 1) Percutaneous 5)
Bronchoscope 2) Vascular catheter 6) Endoscope 3) Stereotactic 7) Arthroscope
4) Sub-retinal
![Page 13: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/13.jpg)
General considerations for the use of somatic gene therapy (approved in 1988)
1. Compensate for a mutation resulting in the
loss of function
examples of monogenic disorders:
cystic fibrosis, hemophilia
![Page 14: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/14.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
examples of monogenic disorders:
cystic fibrosis, hemophilia
stage of the research:
http://clinicaltrials.gov/ct2/results?term=gene+therapy+cystic+fibrosis
![Page 15: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/15.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene
![Page 16: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/16.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene example: Huntington disease (expanded CAG repeat)
? Ribozymes or siRNA to degrade mRNA
![Page 17: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/17.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene example: Huntington disease (expanded CAG repeat)
? Ribozymes or siRNA to degrade mRNA state of research – no open studies for Huntington’s
![Page 18: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/18.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene3. Pharmacologic gene therapy
example: cancer
![Page 19: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/19.jpg)
![Page 20: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/20.jpg)
![Page 21: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/21.jpg)
![Page 22: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/22.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene3. Pharmacologic gene therapy
example: cancer state of research:
clinicaltrials.gov website currently lists 35624 gene therapy trials for cancer; 10649 are open to enrollment
![Page 23: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/23.jpg)
General considerations for the use of gene therapy
1. Compensate for a mutation resulting in the
loss of function
2. Replace or inactivate a dominant mutant gene3. Pharmacologic gene therapy Yet, it is important to note that there is not yet a
single FDA-approved use of gene therapy!
![Page 24: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/24.jpg)
Minimal requirements that must be met:
• Identification of the affected gene
• A cDNA clone encoding the gene
![Page 25: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/25.jpg)
Minimal requirements that must be met:
• Identification of the affected gene
• A cDNA clone encoding the gene
• A substantial disease burden and a favorable risk-benefit ratio
• Sufficient knowledge of the molecular basis of the disease to be confident that the gene transfer will have the desired effect
![Page 26: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/26.jpg)
Minimal requirements that must be met:
• Identification of the affected gene• A cDNA clone encoding the gene• A substantial disease burden and a favorable risk- benefit ratio• Sufficient knowledge of the molecular basis of the disease to be confident that the gene transfer will have the desired effect• Appropriate regulation of the gene expression: tissue specific and levels• Appropriate target cell with either a long half life or high replicative potential• Adequate data from tissue culture and animal studies to support the use of the vector, regulatory sequences, cDNA and target cell
![Page 27: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/27.jpg)
Minimal requirements that must be met:• Identification of the affected gene• A cDNA clone encoding the gene• A substantial disease burden and a favorable risk-benefit ratio• Sufficient knowledge of the molecular basis of the disease to be confident that the gene transfer will have the desired effect• Appropriate regulation of the gene expression: tissue specific and levels• Appropriate target cell with either a long half life or high replicative potential• Adequate data from tissue culture and animal studies to support the use of the vector, regulatory sequences, cDNA and target cell• Appropriate approvals from the institutional and federal review bodies.
![Page 28: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/28.jpg)
Gene therapy• In most gene therapy studies, a "normal"
gene is inserted into the genome to replace an "abnormal," disease-causing gene.
• A carrier molecule called a vector must be used to deliver the therapeutic gene to the patient's target cells. Currently, the most common vector is a virus that has been genetically altered to carry normal human DNA.
![Page 29: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/29.jpg)
Gene Transfer MethodsNon-viral: Expression plasmid or other nucleic acid
(mRNA, siRNA).Challenge: Naked DNA or RNA does not enter cells.
a) Transfer into cells using physical methods such as direct micro-injection or electroporation.
b) complex to carrier to allow cross of cell membrane
liposomes,
cationic lipids,
dextrans,
cyclohexidrins
(aka nanoparticles)
![Page 30: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/30.jpg)
Gene Transfer Methods
Viral vectors = viruses that have been
adapted to serve as gene delivery vectors
include: retrovirus Lenti-virus adenovirus adeno-associated virus (AAV)herpes virus
![Page 31: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/31.jpg)
In Vivo Gene Transfer By AAV Vector
![Page 32: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/32.jpg)
Characteristics of the Ideal Vector for Gene Therapy
• Safe• Sufficient capacity for size of therapeutic DNA• Non-Immunogenic• Allow re-administration• Ease of manipulation• Efficient introduction into target cells/tissues• Efficient and appropriate regulation of expression
•Level, tissue specificity, transient, stable?
![Page 33: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/33.jpg)
Types of viral vectors
• Retrovirus
• Lenti-virus
• Adenovirus
• Adeno-Associated virus (AAV)
• Herpes virus
![Page 34: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/34.jpg)
Types of viral vectorsstable/transient infect non-dividing cells
• Retrovirus stable no
• Lenti-virus stable yes
• Adenovirus transient yes
• Adeno-Associated virus ? yes
• Herpes virus transient yes
![Page 35: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/35.jpg)
Which of the following gene-therapy vectors preferentially infects nerve
cells?A. Adeno-associated virus
B. Retrovirus
C. Herpes virus
D. Adenovirus
E. Liposome
![Page 36: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/36.jpg)
Which of the following gene-therapy vectors preferentially infects nerve
cells?A. Adeno-associated virus
B. Retrovirus
√ C. Herpes virus
D. Adenovirus
E. Liposome
![Page 37: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/37.jpg)
Which of the following vectors targets both dividing and non-dividing cells?
A. Retrovirus
B. Adenovirus
C. Adeno-associated virus
D. Herpes virus
E. Liposome
![Page 38: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/38.jpg)
Which of the following vectors targets both dividing and non-dividing cells?
A. Retrovirus
√ B. Adenovirus
C. Adeno-associated virus
D. Herpes virus
E. Liposome
![Page 39: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/39.jpg)
Choice of target cells is critical
Stem cells
Choice of target cells:
● Long life or substantial replicative potential bone marrow
● Must express an additional proteins needed for biological activity
● Some approaches employ neighboring cells growth factors stimulating repair of nearby heart muscle
![Page 40: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/40.jpg)
In vivo and ex vivo gene therapy
![Page 41: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/41.jpg)
Two strategies for introducing foreign genes into patients
In vivo gene therapyGene therapy vector +
therapeutic gene
Advantages: cells and organs not available ex vivo (lining of the lung)
Disadvantages: virus could spread to other cells/tissues Less control over titer and conditions of exposure
![Page 42: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/42.jpg)
Two strategies for introducing foreign genes into patients
Ex vivo gene therapyStem cells
Gene therapy vector +
Normal gene
Advantages:More controlled infectionhigher titer virus
Disadvantages:technically difficult
![Page 43: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/43.jpg)
Types of viral vectorsstable/transient infect non-dividing cells
• Retrovirus stable no
• Lenti-virus stable yes
• Adenovirus transient yes
• Adeno-Associated virus ? yes
• Herpes virus transient yes
![Page 44: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/44.jpg)
Use of retroviral vectors to introduce therapeutic genes into cells
![Page 45: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/45.jpg)
Use of retroviral vectors to introduce therapeutic genes into cells
![Page 46: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/46.jpg)
Severe Combined Immunodeficiency Syndrome (SCID)——adenine deaminase (ADA) deficiency
![Page 47: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/47.jpg)
Severe Combined Immune Deficiency (SCID)
SCID is popularly known as “bubble baby disease” after a boy with SCID was kept alive for more than a decade in a germ-free room.
SCID is a fatal disease, with infants dying from overwhelming infection due to the congenital absence of a functioning immune system.
More than a dozen genes have been found to be able to cause human SCID.
The first “SCID gene” to be identified in humans is ADA, which makes an enzyme needed forImmune cells to survive.
![Page 48: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/48.jpg)
Severe Combined Immunodeficiency Disease (SCID) is due to a defective gene for Adenosine Deaminase (ADA). A retrovirus, which is capable of transferring it's DNA into normal eukaryotic cells (transfection), is engineered to contain the normal human ADA gene. Isolated T-cell stem line cells from the patient are exposed to the retrovirus in cell culture, and take up the ADA gene. Reimplantation of the transgenic cells into the patient's bone marrow establishes a line of cells with functional ADA, which effecitvely treats SCID.
Ex vivoSomatic Therapy for SCID
![Page 49: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/49.jpg)
ADA deficiency (SCID): Ashanti de
Silva , 1990
![Page 50: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/50.jpg)
Father of GT: Anderson WF, 1990
![Page 51: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/51.jpg)
Geneticist guilty of molestation, 2006
![Page 52: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/52.jpg)
![Page 53: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/53.jpg)
Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease
β-Globin LCRβAS3 Globin
WPRERRE cPPT
ψ
SIN LTR
SIN LTR
HS2 HS3 HS4
Bone Marrow Harvest Isolate Stem CellsAdd Normal
Hemoglobin Gene
Myeloablate with Busulfan (16 mg/kg)
Transplant Gene-Corrected Stem Cells
FreezeCertify
Follow: Safety Efficacy
![Page 54: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/54.jpg)
Gene Therapy Approaches To Cancer
a. Replace missing tumor suppressor genes.
b. Block over-active oncogenes (e.g. siRNA).
c. Insert “suicide genes” (e.g. HSV TK) into tumors.
d. Insert genes to induce anti-tumor immune responses (e.g. IL-2, GM-CSF, CD80).
e. Express genes which impede tumor neo-vasculature.
f. Add chemotherapy resistance genes to HSC to allow chemotherapy dose intensification.
![Page 55: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/55.jpg)
Suicide gene therapy for brain tumors in vivo
• Inject HSV thymidine kinase (tk) gene into tumor cells
• Gancyclovir (nucleoside analog) binds viral gene to block DNA synthesis
• Bystander effect kills surrounding tumor cells
• Takes advantage of the fact that tumor cells are dividing
tk
gancyclovir
![Page 56: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/56.jpg)
Cancer Vaccine Approach
Ex vivo gene therapy
tumor cells
Gene therapy vector +
Cytokine (immune modulator) gene
Irradiated tumor cells transduced with cytokine gene
Time of surgery
![Page 57: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/57.jpg)
Other methods to introduce therapeutic DNA:(approved in 1993)
• Naked DNA
• DNA packed in liposomes(脂质体)• Protein-DNA conjugates (targeting to cell surface receptor
++++ easy to prepare, inexpensive, avoids problems of viral vectors, no size limitations
------- low efficiency in vivo, only transient expression
![Page 58: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/58.jpg)
Risks of Gene Therapy
1.Adverse reaction to vector or gene
1999/9/17: reaction to an adenovirus caused death
of 18-yo man, Jesse Gelsinger, Arizona, the first victim of gene therapy. OTC (ornithine transcarbamylase) important for metabolism of N
Injection of viral particles triggered massive inflammatory response in an individual with mild form of disease being treated with drugs and diet.
Subsequent FDA audit revealed protocol and IRB violations.
![Page 59: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/59.jpg)
Risks of Gene Therapy
2. Activation of harmful genes by viral promoters/enhancers stably integrated into the genome.
2002 retrovirus-induced leukemia
Children with otherwise fatal X-linked SCID injected with ex vivo HSC modified by introduction of the g-c chain cytokine receptor in 2000 (affects lymphocyte maturation)
Initial immune function was good
2/11 patients developed leukemia-like disorder at 2 years.
Clonal analysis shows insertion and activation of LMO2 gene.
FDA-cannot be used as first line therapy if BMT is an option
![Page 60: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/60.jpg)
What factors have kept GT from becoming
an effective treatment for genetic disease?
• Short-lived nature of gene therapy
• Immune response
• Problems with viral vectors • Multigene disorders
![Page 61: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/61.jpg)
RNAi
![Page 62: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/62.jpg)
![Page 63: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/63.jpg)
Patient
Tissue Sample (e.g. skin biopsy)
Gene Addition or Gene Correction
De-Differentiation to Induced Pluripotent Stem cells (iPS)
Differentiation to Hematopoietic Stem Cells (HSC)
Autologous Transplant
Gene therapy using Autologous HSC Made from Induced Pluripotent Stem Cells
![Page 64: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/64.jpg)
Gene Therapy
Current Future
Experimental Proven
Limited Scope Curative
High Tech Off the Shelf
![Page 65: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/65.jpg)
Gene Therapy Clinical Trials Worldwide (updated list of all
gene therapy protocols)
www.wiley.com/legacy/wileychi/genmed/clinical/
![Page 66: Gene Therapy 张咸宁 zhangxianning@zju.edu.cn Tel : 13105819271; 88208367 Office: A705, Research Building 2012/09.](https://reader033.fdocuments.net/reader033/viewer/2022061518/56649e055503460f94af1b7b/html5/thumbnails/66.jpg)
Acknowledge ( PPT特别鸣谢!)
• UCLA David Geffen School of Medicine
• www.medsch.ucla.edu/ANGEL/
• Prof. KohnProf. Kohn DB (Department ofDepartment of Microbiology, Immunology and Microbiology, Immunology and Molecular Genetics (MIMG)Molecular Genetics (MIMG) ), Prof. Prof. Gasson JC ((UCLA Jonsson Comprehensive Cancer Center ), et al.), et al.